Clozapine-induced serositis: review of its clinical features, pathophysiology and management strategies.
Although the benefits of clozapine have been well demonstrated in resistant schizophrenia, the frequency of adverse events is of particular concern: up to 76% of patients to whom clozapine was prescribed experienced an adverse event, with a discontinuation rate of 17%. In addition to its major clinical side effect, agranulocytosis, clozapine is reported to induce inflammatory syndromes with polyserositis. Apart from sparse case reports, no study has yet addressed this particularly interesting issue. With the aim of improving the outcome of clozapine-treated patients, we undertook a review of the literature to characterize the clinical features of clozapine-induced serositis, its pathophysiology, and to propose strategies of clinical management.
Mouaffak
Fayçal
F
Center of Psychiatry and Neurosciences, INSERM U894. mouaffakf@yahoo.fr
Gaillard
Raphael
R
Burgess
Elizabeth
E
Zaki
Hanane
H
Olié
Jean Pierre
JP
Krebs
Marie-Odile
MO
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D003024:Clozapine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D012700:Serositis / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D028761:Withholding Treatment
D014150:Antipsychotic Agents; D003024:Clozapine